S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:PRVL

Prevail Therapeutics Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.
$23.00
0.00 (0.00 %)
(As of 01/22/2021)
Add
Compare
Today's Range
$23.00
Now: $23.00
$23.00
50-Day Range
$22.91
MA: $23.01
$23.20
52-Week Range
$9.02
Now: $23.00
$23.35
VolumeN/A
Average Volume955,800 shs
Market Capitalization$787.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59

Competitors

Prevail Therapeutics (NASDAQ:PRVL) Vs. RVMD, NK, EDIT, NSTG, SRNE, and ALVR

Should you be buying PRVL stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Prevail Therapeutics, including Revolution Medicines (RVMD), NantKwest (NK), Editas Medicine (EDIT), NanoString Technologies (NSTG), Sorrento Therapeutics (SRNE), and AlloVir (ALVR).

Prevail Therapeutics (NASDAQ:PRVL) and Revolution Medicines (NASDAQ:RVMD) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares Prevail Therapeutics and Revolution Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prevail TherapeuticsN/A-55.57%-48.14%
Revolution Medicines-191.17%-32.25%-20.55%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Prevail Therapeutics and Revolution Medicines, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prevail Therapeutics07302.30
Revolution Medicines01402.80

Prevail Therapeutics currently has a consensus price target of $23.5714, suggesting a potential upside of 2.48%. Revolution Medicines has a consensus price target of $50.75, suggesting a potential upside of 19.55%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Revolution Medicines is more favorable than Prevail Therapeutics.

Earnings and Valuation

This table compares Prevail Therapeutics and Revolution Medicines' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prevail TherapeuticsN/AN/A$-63,190,000.00($2.22)-10.36
Revolution Medicines$50.04 million56.31$-47,660,000.00N/AN/A

Revolution Medicines has higher revenue and earnings than Prevail Therapeutics.

Insider and Institutional Ownership

86.8% of Prevail Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Revolution Medicines shares are held by institutional investors. 57.2% of Prevail Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Revolution Medicines beats Prevail Therapeutics on 7 of the 10 factors compared between the two stocks.

NantKwest (NASDAQ:NK) and Prevail Therapeutics (NASDAQ:PRVL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares NantKwest and Prevail Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NantKwest-76,658.58%-56.06%-46.93%
Prevail TherapeuticsN/A-55.57%-48.14%

Volatility and Risk

NantKwest has a beta of 2.61, meaning that its share price is 161% more volatile than the S&P 500. Comparatively, Prevail Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for NantKwest and Prevail Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NantKwest00103.00
Prevail Therapeutics07302.30

NantKwest currently has a consensus price target of $18.00, indicating a potential downside of 30.10%. Prevail Therapeutics has a consensus price target of $23.5714, indicating a potential upside of 2.48%. Given Prevail Therapeutics' higher possible upside, analysts plainly believe Prevail Therapeutics is more favorable than NantKwest.

Insider & Institutional Ownership

9.4% of NantKwest shares are held by institutional investors. Comparatively, 86.8% of Prevail Therapeutics shares are held by institutional investors. 71.7% of NantKwest shares are held by insiders. Comparatively, 57.2% of Prevail Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares NantKwest and Prevail Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NantKwest$40,000.0070,166.82$-65,790,000.00($0.70)-36.79
Prevail TherapeuticsN/AN/A$-63,190,000.00($2.22)-10.36

Prevail Therapeutics has lower revenue, but higher earnings than NantKwest. NantKwest is trading at a lower price-to-earnings ratio than Prevail Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Prevail Therapeutics beats NantKwest on 7 of the 13 factors compared between the two stocks.

Prevail Therapeutics (NASDAQ:PRVL) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Valuation & Earnings

This table compares Prevail Therapeutics and Editas Medicine's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prevail TherapeuticsN/AN/A$-63,190,000.00($2.22)-10.36
Editas Medicine$20.53 million132.43$-133,750,000.00($2.68)-15.06

Prevail Therapeutics has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Prevail Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prevail Therapeutics and Editas Medicine's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prevail TherapeuticsN/A-55.57%-48.14%
Editas Medicine-99.62%-26.74%-16.38%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Prevail Therapeutics and Editas Medicine, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prevail Therapeutics07302.30
Editas Medicine34302.00

Prevail Therapeutics presently has a consensus target price of $23.5714, indicating a potential upside of 2.48%. Editas Medicine has a consensus target price of $49.2222, indicating a potential upside of 21.96%. Given Editas Medicine's higher probable upside, analysts clearly believe Editas Medicine is more favorable than Prevail Therapeutics.

Risk & Volatility

Prevail Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500.

Institutional & Insider Ownership

86.8% of Prevail Therapeutics shares are owned by institutional investors. Comparatively, 87.5% of Editas Medicine shares are owned by institutional investors. 57.2% of Prevail Therapeutics shares are owned by company insiders. Comparatively, 0.9% of Editas Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Prevail Therapeutics (NASDAQ:PRVL) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for Prevail Therapeutics and NanoString Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prevail Therapeutics07302.30
NanoString Technologies01502.83

Prevail Therapeutics presently has a consensus price target of $23.5714, suggesting a potential upside of 2.48%. NanoString Technologies has a consensus price target of $63.00, suggesting a potential upside of 3.26%. Given NanoString Technologies' stronger consensus rating and higher probable upside, analysts plainly believe NanoString Technologies is more favorable than Prevail Therapeutics.

Volatility and Risk

Prevail Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.

Profitability

This table compares Prevail Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prevail TherapeuticsN/A-55.57%-48.14%
NanoString Technologies-53.47%-68.96%-24.15%

Valuation & Earnings

This table compares Prevail Therapeutics and NanoString Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prevail TherapeuticsN/AN/A$-63,190,000.00($2.22)-10.36
NanoString Technologies$125.57 million21.41$-40,700,000.00($1.93)-31.61

NanoString Technologies has higher revenue and earnings than Prevail Therapeutics. NanoString Technologies is trading at a lower price-to-earnings ratio than Prevail Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

86.8% of Prevail Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of NanoString Technologies shares are owned by institutional investors. 57.2% of Prevail Therapeutics shares are owned by company insiders. Comparatively, 4.2% of NanoString Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

NanoString Technologies beats Prevail Therapeutics on 9 of the 13 factors compared between the two stocks.

Prevail Therapeutics (NASDAQ:PRVL) and Sorrento Therapeutics (NASDAQ:SRNE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Volatility & Risk

Prevail Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.7, meaning that its share price is 170% more volatile than the S&P 500.

Profitability

This table compares Prevail Therapeutics and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prevail TherapeuticsN/A-55.57%-48.14%
Sorrento Therapeutics-698.01%-314.06%-43.60%

Insider and Institutional Ownership

86.8% of Prevail Therapeutics shares are held by institutional investors. Comparatively, 27.4% of Sorrento Therapeutics shares are held by institutional investors. 57.2% of Prevail Therapeutics shares are held by insiders. Comparatively, 3.4% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Prevail Therapeutics and Sorrento Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prevail TherapeuticsN/AN/A$-63,190,000.00($2.22)-10.36
Sorrento Therapeutics$31.43 million78.73$-292,070,000.00($2.12)-4.16

Prevail Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics. Prevail Therapeutics is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Prevail Therapeutics and Sorrento Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prevail Therapeutics07302.30
Sorrento Therapeutics00403.00

Prevail Therapeutics presently has a consensus price target of $23.5714, suggesting a potential upside of 2.48%. Sorrento Therapeutics has a consensus price target of $28.75, suggesting a potential upside of 226.33%. Given Sorrento Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sorrento Therapeutics is more favorable than Prevail Therapeutics.

Summary

Sorrento Therapeutics beats Prevail Therapeutics on 8 of the 13 factors compared between the two stocks.

AlloVir (NASDAQ:ALVR) and Prevail Therapeutics (NASDAQ:PRVL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Analyst Recommendations

This is a summary of recent recommendations for AlloVir and Prevail Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AlloVir00403.00
Prevail Therapeutics07302.30

AlloVir presently has a consensus target price of $48.75, indicating a potential upside of 41.18%. Prevail Therapeutics has a consensus target price of $23.5714, indicating a potential upside of 2.48%. Given AlloVir's stronger consensus rating and higher probable upside, analysts clearly believe AlloVir is more favorable than Prevail Therapeutics.

Institutional & Insider Ownership

32.1% of AlloVir shares are held by institutional investors. Comparatively, 86.8% of Prevail Therapeutics shares are held by institutional investors. 1.0% of AlloVir shares are held by company insiders. Comparatively, 57.2% of Prevail Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares AlloVir and Prevail Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AlloVirN/AN/AN/AN/AN/A
Prevail TherapeuticsN/AN/A$-63,190,000.00($2.22)-10.36

Profitability

This table compares AlloVir and Prevail Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AlloVirN/AN/AN/A
Prevail TherapeuticsN/A-55.57%-48.14%

Summary

AlloVir beats Prevail Therapeutics on 5 of the 7 factors compared between the two stocks.


Prevail Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$42.45flat$2.82 billion$50.04 million0.00Earnings Announcement
Analyst Report
NantKwest logo
NK
NantKwest
1.1$25.75flat$2.81 billion$40,000.00-36.27Decrease in Short Interest
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$40.36flat$2.72 billion$20.53 million-23.20Analyst Report
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$61.01flat$2.69 billion$125.57 million-35.68Earnings Announcement
Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.81flat$2.47 billion$31.43 million-6.03Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.53flat$2.25 billionN/A0.00Insider Selling
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$45.86flat$2.04 billionN/A0.00
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$10.92flat$1.94 billion$48.83 million-14.37
bluebird bio logo
BLUE
bluebird bio
1.8$27.94flat$1.88 billion$44.67 million-2.54Analyst Report
Vericel logo
VCEL
Vericel
1.5$40.41flat$1.86 billion$117.85 million-4,041,000.00Analyst Report
Analyst Revision
Scholar Rock logo
SRRK
Scholar Rock
1.3$50.60flat$1.70 billion$20.49 million-21.00Upcoming Earnings
News Coverage
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.97flat$1.69 billionN/A-6.06Analyst Report
Unusual Options Activity
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.07flat$1.68 billionN/A0.00
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.23flat$1.61 billion$102.43 million-18.72Analyst Downgrade
Analyst Revision
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.65flat$1.59 billionN/A-48.41Earnings Announcement
Analyst Upgrade
Analyst Revision
Translate Bio logo
TBIO
Translate Bio
1.4$21.29flat$1.58 billion$7.80 million-19.90Upcoming Earnings
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$32.30flat$1.50 billionN/A-18.25News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$39.21flat$1.47 billion$35.23 million-15.81Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$33.42flat$1.38 billion$100.56 million0.00Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.89flat$1.33 billionN/A-3.44Earnings Announcement
Analyst Upgrade
Analyst Revision
Alector logo
ALEC
Alector
1.3$16.25flat$1.29 billion$21.22 million-7.29Analyst Upgrade
Immunovant logo
IMVT
Immunovant
1.8$13.08flat$1.28 billionN/A-10.14Increase in Short Interest
PCVX
Vaxcyte
1.8$23.62flat$1.20 billionN/A0.00Insider Selling
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.25flat$1.11 billion$356.07 million7.47Analyst Report
Mesoblast logo
MESO
Mesoblast
1.4$9.18flat$1.08 billion$32.16 million-10.43Earnings Announcement
Analyst Upgrade
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$36.37flat$1.07 billionN/A-15.15Earnings Announcement
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$10.96flat$1.07 billion$250,000.00-8.63Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.56flat$1.00 billionN/A0.00
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$19.25flat$903.15 million$69.89 million-4.59
Passage Bio logo
PASG
Passage Bio
1.9$19.43flat$892.17 millionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.40flat$883.61 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$23.73flat$857.03 millionN/A-3.92News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.7$10.40flat$844.29 millionN/A-4.86
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54flat$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31flat$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06flat$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29flat$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01flat$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92flat$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86flat$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29flat$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61flat$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16flat$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02flat$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28flat$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16flat$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02flat$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13flat$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90flat$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83flat$533.77 millionN/A-4.29Upcoming Earnings
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.